Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Akili, Inc. - Common Stock (NQ: AKLI )

0.3845 +0.1496 (+63.69%)
Streaming Delayed Price Updated: 1:24 PM EDT, Apr 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Akili, Inc. - Common Stock

< Previous 1 2 Next >
Akili Announces Amended Agreement with Shionogi, Shift in Corporate Strategy and Release Date for First Quarter 2024 Financial Results
From Akili, Inc.
Via Business Wire
Akili Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From Akili, Inc.
Via Business Wire
PureTech Founded Entity Akili Announces Positive Results from Shionogi’s Phase 3 Clinical Trial of Localized Version of Akili’s EndeavorRx ® for Pediatric ADHD Patients in Japan
From PureTech Health plc
Via Business Wire
Akili Announces Positive Results from Shionogi’s Phase 3 Clinical Trial of Localized Version of Akili’s EndeavorRx® for Pediatric ADHD Patients in Japan
From Akili, Inc.
Via Business Wire
Akili Announces Release Date for Fourth Quarter and Full Year 2023 Financial Results, Provides Investor Communications and Board and Corporate Governance Updates
From Akili, Inc.
Via Business Wire
EndeavorRxⓇ, World’s First and Only Prescription Video Game Treatment, Secures FDA Label Expansion for Pediatric ADHD Patients Aged 13-17
From Akili, Inc.
Via Business Wire
Akili Reports Third Quarter 2023 Financial Results and Provides Business Update
From Akili, Inc.
Via Business Wire
Akili to Host Third Quarter Financial Results Conference Call and Webcast on Thursday, November 9 at 4:30 p.m. ET
From Akili, Inc.
Via Business Wire
Employees with ADHD Aren’t Reaching Their Full Potential at Work, Akili Study Finds
From Akili, Inc.
Via Business Wire
Akili Announces Leadership Transition
From Akili, Inc.
Via Business Wire
Akili Releases EndeavorOTC™ on Android™ Devices, Expanding Treatment Access for Millions of Adults with ADHD
From Akili, Inc.
Via Business Wire
Akili Announces Business Transformation, Focusing on Non-prescription Model
From Akili, Inc.
Via Business Wire
Akili Reports Second Quarter 2023 Financial Results and Provides Business Update
From Akili, Inc.
Via Business Wire
Akili to Host Second Quarter Financial Results Conference Call and Webcast on Thursday, August 10 at 4:30 p.m. ET
From Akili, Inc.
Via Business Wire
Akili Releases EndeavorOTCTM Video Game Treatment to Improve Attention in Adults with ADHD
From Akili, Inc.
Via Business Wire
Akili to Present Clinical Data from Pivotal Trial of Video Game Treatment in Adolescents with ADHD at 2023 ASCP Annual Meeting and Elevate Psych Congress
From Akili, Inc.
Via Business Wire
Akili Reports First Quarter 2023 Financial Results and Provides Business Update
From Akili, Inc.
Via Business Wire
PureTech Founded Entity Akili Announces Adults with ADHD See Significant Improvements in Attention, ADHD Symptoms, and Quality of Life in Clinical Trial of Akili’s EndeavorRx® Video Game-Based Therapeutic
From PureTech Health plc
Via Business Wire
Adults with ADHD See Significant Improvements in Attention, ADHD Symptoms, and Quality of Life in Clinical Trial of Akili’s EndeavorRx® Video Game-Based Therapeutic
From Akili, Inc.
Via Business Wire
Akili to Host First Quarter Financial Results Conference Call and Webcast on Thursday, May 11 at 4:30 p.m. ET
From Akili, Inc.
Via Business Wire
Akili Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
From Akili, Inc.
Via Business Wire
Akili to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast on Tuesday, March 7 at 4:30 p.m. ET
From Akili, Inc.
Via Business Wire
Akili to Participate in the Cowen 43rd Annual Health Care Conference
From Akili, Inc.
Via Business Wire
Akili to Champion Digital Therapeutics in Conjunction with J.P. Morgan Healthcare Conference
From Akili, Inc.
Via Business Wire
Pivotal Trial of EndeavorRxⓇ in Adolescents with ADHD Shows Robust Improvements in Attention and Broader Clinical Outcomes
From Akili, Inc.
Via Business Wire
Akili Announces ADHD Expert Dr. Scott Kollins to Join as Chief Medical Officer
From Akili, Inc.
Via Business Wire
Akili Reports Third Quarter 2022 Financial Results and Company Update
From Akili, Inc.
Via Business Wire
Financial Industry Veteran Mary Hentges Joins Akili’s Board of Directors
From Akili, Inc.
Via Business Wire
Akili to Host Third Quarter 2022 Financial Results Conference Call and Webcast on Thursday, November 10 at 4:30 p.m. ET
From Akili, Inc.
Via Business Wire
Akili Launches EndeavorRx® Expedition - A Direct-to-Patient Product Registry
From Akili, Inc.
Via Business Wire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.